CN102429861A - Double-cavity bag packaged cefradine injection and preparation method thereof - Google Patents
Double-cavity bag packaged cefradine injection and preparation method thereof Download PDFInfo
- Publication number
- CN102429861A CN102429861A CN2011103864026A CN201110386402A CN102429861A CN 102429861 A CN102429861 A CN 102429861A CN 2011103864026 A CN2011103864026 A CN 2011103864026A CN 201110386402 A CN201110386402 A CN 201110386402A CN 102429861 A CN102429861 A CN 102429861A
- Authority
- CN
- China
- Prior art keywords
- injection
- cefradine
- bag
- powder
- chamber
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960002588 cefradine Drugs 0.000 title claims abstract description 54
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 title claims abstract description 54
- 239000007924 injection Substances 0.000 title claims abstract description 28
- 238000002347 injection Methods 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims description 17
- 239000000843 powder Substances 0.000 claims abstract description 84
- 238000000034 method Methods 0.000 claims abstract description 35
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 29
- 230000008569 process Effects 0.000 claims abstract description 28
- 229940090044 injection Drugs 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 24
- 229940093181 glucose injection Drugs 0.000 claims abstract description 16
- 239000007788 liquid Substances 0.000 claims abstract description 16
- 239000008354 sodium chloride injection Substances 0.000 claims abstract description 14
- 239000008103 glucose Substances 0.000 claims abstract description 13
- 239000011780 sodium chloride Substances 0.000 claims abstract description 12
- 230000001954 sterilising effect Effects 0.000 claims description 27
- 238000003466 welding Methods 0.000 claims description 27
- 238000007789 sealing Methods 0.000 claims description 22
- 238000004659 sterilization and disinfection Methods 0.000 claims description 19
- 238000012856 packing Methods 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 11
- 238000005303 weighing Methods 0.000 claims description 9
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 7
- 229910052782 aluminium Inorganic materials 0.000 claims description 7
- 239000002131 composite material Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000008215 water for injection Substances 0.000 claims description 7
- 238000010030 laminating Methods 0.000 claims description 6
- 239000005030 aluminium foil Substances 0.000 claims description 3
- 238000009434 installation Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims 2
- 229940069981 azithromycin injection Drugs 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 5
- 239000002904 solvent Substances 0.000 abstract description 5
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 abstract description 4
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 abstract description 4
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 abstract description 4
- 238000005192 partition Methods 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 238000005286 illumination Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- 108010087702 Penicillinase Proteins 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 229950009506 penicillinase Drugs 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- SCNWTQPZTZMXBG-UHFFFAOYSA-N 2-methyloct-2-enoic acid Chemical compound CCCCCC=C(C)C(O)=O SCNWTQPZTZMXBG-UHFFFAOYSA-N 0.000 description 1
- -1 4-cyclohexenyl Chemical group 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241001312524 Streptococcus viridans Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 208000016150 acute pharyngitis Diseases 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000022760 infectious otitis media Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Images
Landscapes
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a cefradine injection packed by a double-cavity bag, which comprises the following raw material medicaments: powder cavity: 0.1-2 parts by weight of cefradine; liquid cavity: glucose injection: 100 volume parts of glucose-containing 4-11 weight parts or sodium chloride injection: 100 parts by volume of sodium chloride, 0.8-1 part by weight of sodium chloride; the cefradine injection is packaged by adopting a double-cavity bag, and the cefradine sterile powder and the solvent (sodium chloride injection or glucose injection) are respectively filled in two cavities separated by a rosin joint partition, so that the rosin joint isolating strip can be opened by only extruding the medicine bag when the cefradine sterile powder injection is used, the cefradine sterile powder and the solvent can quickly complete the dissolving and mixing process under the closed sterile condition, and the full-medicament treatment mixed liquid is formed and directly used for a patient.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition and preparation method thereof, cefradine injection of particularly a kind of two-chamber bag packing and preparation method thereof.
Background technology
The cefradine chemical name is: (6R; 7R)-7 [(R)-2-amino-2-(1; The 4-cyclohexenyl group) acetylamino]-3-methyl-8-oxo-5-thia-1-azabicyclo [4,2,0] oct-2-ene-2-carboxylic acid; Be first generation cephalosporin, to not producing penicillinase and the good antibacterial action of part bacterial strain tool that produces penicillinase gold Portugal bacterium, CN-S, GPCs such as A group Hemolytic streptococcus, streptococcus pneumoniae and Streptococcus viridans.How responsive the anaerobism gram positive bacteria is to these article, and bacteroides fragilis presents drug resistance to these article.Methicillin-resistant staphylococcus, Enterococcus are to this article drug resistance.Cefradine is similar with cefalexin with the effect of gram-negative bacteria to gram positive bacteria.These article have certain effect to gonococcus, and also tool is active to producing the enzyme gonococcus; Active relatively poor to hemophilus influenza.Be applicable to respiratory tract infection such as acute pharyngitis, tonsillitis, otitis media, bronchitis and pneumonia, urogenital infections and skin soft-tissue infection etc. due to the sensitive organism.
The main at home and abroad dosage form of this product is at present: freeze-dried powder, aseptic subpackaged powder pin, small-volume injection etc.; Above-mentioned preparation in being infused to the patient body before; Must use appropriate solvent (sodium chloride injection as 0.9% or 5% glucose injection) that its dissolving or dilution are become the solution that concentration is lower than 2mg/ml; Just can carry out intravenous drip, and the process of dissolving and dilution is consuming time relatively, under specific conditions such as war or emergency aid and treatment; Often because the process of making up a prescription is loaded down with trivial details, intravenously administrable fast; The on-the-spot area of rescue equipment is narrow, advances and jolts, and is difficult for carrying out malpraxis or accidents such as the dispensing operation or the mistake of making up a prescription; Give first aid to on-the-spot air and particle contamination, be prone to cause secondary pollution; Medicine is a glass bottle packaging, is prone to broken and can't drops; There is the existence of problems such as medicine and carrier transfusion quantity, effect phase coupling in the war storage, causes the environment at the scene of giving treatment to and time all not to reach conventional transfusion preparation necessary requirement.
The freeze-dried powder of market sale, aseptic subpackaged powder pin all adopt the cillin bottle packing; Seal with butyl rubber plug; In the medicine storage and transport process, when medicated powder with after plug contacts, in the plug additive composition possibly separate out or with medicated powder generation physics or chemical reaction; It is defective to cause clarity of solution to investigate the result, influences the safety that product uses.
Summary of the invention
The object of the invention has been to provide a kind of cefradine injection that adopts two-chamber bag packing and preparation method thereof.
The present invention seeks to realize through following technical scheme:
The crude drug of injection pharmaceutical composition of the present invention consists of:
Powder chamber: cefradine 0.5～2 weight portion
Sap cavity: glucose injection: 100 parts by volume contain glucose 4～11 weight portions or sodium chloride injection: 100 parts by volume contain 0.8～1 weight portion
Above-mentioned raw materials medicine preferred weight proportioning is following:
Powder chamber: cefradine 1 weight portion
Sap cavity: glucose injection: 100 parts by volume contain glucose 5 weight portions
Above-mentioned raw materials medicine preferred weight proportioning is following:
Powder chamber: cefradine 0.5 weight portion
Sap cavity: glucose injection: 250 parts by volume contain glucose 12.5 weight portions
Above-mentioned raw materials medicine preferred weight proportioning is following:
Powder chamber: cefradine 2 weight portions
Sap cavity: sodium chloride injection: 100 parts by volume sodium chloride-containing, 0.9 weight portion
Above-mentioned raw materials medicine preferred weight proportioning is following:
Powder chamber: cefradine 0.5 weight portion
Sap cavity: sodium chloride injection: 250 parts by volume sodium chloride-containing, 2.25 weight portions
The concrete production technology of the present invention is following:
Bag forming: use the film for transfusion of double-layer seal to process bag, the bag edge adopts real weldering sealing, and reserves the interface that is used for fill, is divided into two chambers of exerting pressure and can open with weak welding rod in the middle of the bag.
The medicinal liquid preparation
The preparation of glucose injection: take by weighing glucose by formula ratio and add an amount of water for injection to process concentration be 4%～11% solution.
The preparation of sodium chloride injection: take by weighing sodium chloride by formula ratio and add an amount of water for injection to process concentration be 0.8%～1% solution.
Liquid medicine filling, seal: the medicinal liquid for preparing is poured into the transfusion bag sap cavity through interface, and seal.
Sterilization: packaged sample is placed sterilizing installation, in 115 ℃～125 ℃ sterilizations 8～30 minutes.
Dry: the sample after will sterilizing descended dry 60-150 minute in 70-100 ℃.
The fill of aseptic powder: sample is fixed on the powder dispensing apparatus, under gnotobasis, cuts real welding rod on one side, the cefradine aseptic powder is quantitatively poured into the powder chamber after, firm slit edge edge is carried out real sealing mouth.
The welding of aluminium foil outside the powder chamber: aluminum film and powder chamber are welded all around, thereby form a kind of special protection structure, make it can block oxygen, water vapour and illumination in outside, powder chamber.
Cefradine injection of the present invention adopts two-chamber bag packing; Through cefradine aseptic powder and solvent (sodium chloride injection or glucose injection) being distinguished fill in cutting off with rosin joint in two chambers that separate; Only need push medicated bag during use; Can open the rosin joint isolating bar, make cefradine aseptic powder and solvent under airtight aseptic condition, accomplish rapidly dissolving mixed process, form full Drug therapy mixed liquor and directly be used for the patient.
The present invention can avoid with cefradine process directly that the related substance that very easily occurs behind the bulk capacity injection increases and active constituent content under the degradation problem and also since the cefradine medicated powder in the powder chamber only contact with the film material; The packaging material composition is compared simple relatively with the used cillin bottle plug of conventional powder; Avoided in the packaging material complicated additive composition to separate out or react with medicated powder; Prolonged keeping life greatly; Significantly strengthen the environmental suitability of medicine, kept bulk capacity injection to need not the less relatively advantage of dissolved dilution, secondary pollution, can effectively improve the actual effect and the safety of cefradine intravenously administrable under emergency rating.
Description of drawings
Accompanying drawing 1: two-chamber bag plane graph;
Indicate among the figure: 1-powder chamber, the weak welding rod of 2-, 3-sap cavity, 4-composite cover
Accompanying drawing 2: process chart.
Experimental example 1
Adopt the sample of embodiment 1 preparation to be respectively charged in glass infusion bottle and the two-chamber bag; The laggard line stabilization property investigation of sterilizing; Can find; Sample is after the sterilization, after 40 ℃ of accelerated tests investigate and June, 25 ℃ of long term tests investigate December, and each item index of the sample of two-chamber bag packing has no significant change, and stability obviously is superior to glass infusion bottle packing sample.(as shown in table 1)
Table 1 product stability is investigated comparing result
Experimental example 2
(XiLin is bottled to get 10 cefradine powder pins respectively; Specification: 0.5g) with 10 bottles of glucose injections (glass transfusion bottle, specification: 100ml:0.5g), according to the clinical manipulation method of routine; Change the cefradine aseptic powder over to glucose injection, and it is dissolved fully; Other gets 10 bags of two-chamber bag samples that adopt embodiment 1 preparation, opens weak welding rod, and jolting is dissolved the cefradine aseptic powder fully, and operating process is compared investigation.(as shown in table 2, test data is the meansigma methods of 10 tests.)
Table 2
Can know by comparing result; Adopt the cefradine preparation of existing ordinary packing, operation relative complex, environmental requirement higher (the general requirement of large hospital operated at the clean operating board that the laminar flow protection is arranged at present); And be easy to generate particulate matter, cause potential hazards such as thrombosis and granuloma; And the cefradine injection that adopts two chambers bag to pack is more convenient to operate, quick, because medicinal liquid is enclosed among the bag all the time, environmental requirement is low, is convenient to special occasions and implements first aid; Owing to need not solution transfer, the particulate matter of generation is far below the product that adopts ordinary packing, and is littler to patient's potential hazard, uses safer simultaneously.
Experimental example 3
(XiLin is bottled to get the cefradine powder pin of two producers respectively; Specification: 0.5g) each 50 and 50 bags in two-chamber bag sample adopting embodiment 1 preparation, place simultaneously under 40 ℃ of accelerated test conditions and investigate June, all samples all adopts the mode of putting upside down; Take out respectively acceleration 0,1,2,3, June by 10 (bags); The cefradine aseptic powder is mixed with the solubility of 0.1g/ml with purified water, observes the clarity of solution, result such as table 3:
Table 3
Investigation data by last table can be known, adopt two chambers bag packaged products, and the clarity of cefradine aseptic powder is investigated the cillin bottle packaging product that the result obviously is superior to present list marketing, therefore adopt two chamber bag packaged products safeties higher.
Analyzing its reason, possibly be because the plug composition is more complicated than film for transfusion, with process that medicated powder for a long time contacts in, in the plug additive composition possibly separate out or with medicine part generation physics or chemical reaction, cause clarity of solution investigation result defective.
Embodiment 1
Powder chamber: cefradine 0.5g
Sap cavity: glucose injection: 100ml:5g
Use the film for transfusion of double-layer seal, process bag through the multicell bag making, filling and sealing machine, the bag edge adopts real weldering sealing, and reserves the interface that is used for fill, is divided into two chambers (can exert pressure and open) with weak welding rod in the middle of the bag.Taking by weighing glucose 5g adds the injection water and is settled to 100ml to process concentration be 5% solution.The medicinal liquid for preparing is poured into the transfusion bag sap cavity through interface, and the suitable accessory of welding composite cover or other seals.Packaged sample is placed steam autoclave, in 121 ℃ of sterilizations 12 minutes.Sample after the sterilization is following dry 80 minutes in 80 ℃.Sample is fixed on the full-automatic powder racking machine, under gnotobasis, cuts real welding rod on one side, the cefradine aseptic powder is poured into the powder chamber after, firm slit edge edge is carried out real sealing mouth.Adopt full-automatic laminating machine that aluminum film and powder chamber are welded all around, thereby form a kind of special protection structure, make it can block certain oxygen, water vapour and illumination, avoid powder intracavity drug powder is impacted in outside, powder chamber.
Embodiment 2
Powder chamber: cefradine 0.5g
Sap cavity: glucose injection: 250ml:12.5g
Use the film for transfusion of double-layer seal, process bag through the multicell bag making, filling and sealing machine, the bag edge adopts real weldering sealing, and reserves the interface that is used for fill, is divided into two chambers (can exert pressure and open) with weak welding rod in the middle of the bag.Taking by weighing glucose 12.5g adds 250ml water for injection to process concentration is 5% solution.The medicinal liquid for preparing is poured into the transfusion bag sap cavity through interface, and the suitable accessory of welding composite cover or other seals.Packaged sample is placed steam autoclave, in 115 ℃～125 ℃ sterilizations 8～30 minutes.Sample after the sterilization was descended dry 60-150 minute in 70-100 ℃.Sample is fixed on the full-automatic powder racking machine, under gnotobasis, cuts real welding rod on one side, the cefradine aseptic powder is poured into the powder chamber after, firm slit edge edge is carried out real sealing mouth.Adopt full-automatic laminating machine that aluminum film and powder chamber are welded all around, thereby form a kind of special protection structure, make it can block certain oxygen, water vapour and illumination, avoid powder intracavity drug powder is impacted in outside, powder chamber.
Embodiment 3
Powder chamber: cefradine 1g
Sap cavity: sodium chloride injection: 100ml:0.9g
Use the film for transfusion of double-layer seal, process bag through the multicell bag making, filling and sealing machine, the bag edge adopts real weldering sealing, and reserves the interface that is used for fill, is divided into two chambers (can exert pressure and open) with weak welding rod in the middle of the bag.Taking by weighing sodium chloride 0.9g by formula ratio adds 100ml water for injection to process concentration is 0.9% solution.The medicinal liquid for preparing is poured into the transfusion bag sap cavity through interface, and the suitable accessory of welding composite cover or other seals.Packaged sample is placed steam autoclave, in 115 ℃～125 ℃ sterilizations 8～30 minutes.Sample after the sterilization was descended dry 60-150 minute in 70-100 ℃.Sample is fixed on the full-automatic powder racking machine, under gnotobasis, cuts real welding rod on one side, the cefradine aseptic powder is poured into the powder chamber after, firm slit edge edge is carried out real sealing mouth.Adopt full-automatic laminating machine that aluminum film and powder chamber are welded all around, thereby form a kind of special protection structure, make it can block certain oxygen, water vapour and illumination, avoid powder intracavity drug powder is impacted in outside, powder chamber.
Embodiment 4
Powder chamber: cefradine 2g
Sap cavity: sodium chloride injection: 250ml:2.25g
Use the film for transfusion of double-layer seal, process bag through the multicell bag making, filling and sealing machine, the bag edge adopts real weldering sealing, and reserves the interface that is used for fill, is divided into two chambers (can exert pressure and open) with weak welding rod in the middle of the bag.Taking by weighing sodium chloride 2.25g adds 250ml water for injection to process concentration is 0.9% solution.The medicinal liquid for preparing is poured into the transfusion bag sap cavity through interface, and the suitable accessory of welding composite cover or other seals.Packaged sample is placed steam autoclave, in 115 ℃～125 ℃ sterilizations 8～30 minutes.Sample after the sterilization was descended dry 60-150 minute in 70-100 ℃.Sample is fixed on the full-automatic powder racking machine, under gnotobasis, cuts real welding rod on one side, the cefradine aseptic powder is poured into the powder chamber after, firm slit edge edge is carried out real sealing mouth.Adopt full-automatic laminating machine that aluminum film and powder chamber are welded all around, thereby form a kind of special protection structure, make it can block certain oxygen, water vapour and illumination, avoid powder intracavity drug powder is impacted in outside, powder chamber.
Claims (8)
1. the cefradine injection of two-chamber bag packing is characterized in that the crude drug of this injection pharmaceutical composition consists of:
Powder chamber: cefradine 0.1～2 weight portion
Sap cavity: glucose injection: 100 parts by volume contain glucose 4～11 weight portions or
Sodium chloride injection: 100 parts by volume sodium chloride-containing, 0.8～1 weight portion sodium chloride;
Use the film for transfusion of double-layer seal to process bag, the bag edge adopts real weldering sealing, and reserves the interface that is used for fill, is divided into two chambers of exerting pressure and can open with weak welding rod in the middle of the bag; Liquid medicine filling, seal: the medicinal liquid for preparing is poured into the transfusion bag sap cavity through interface, and seal; Sterilization: packaged sample is placed sterilizing installation, in 115 ℃～125 ℃ sterilizations 8～30 minutes; Dry: the sample after will sterilizing descended dry 60-150 minute in 70-100 ℃; The relation of said weight portion and parts by volume is the relation of g/ml.
2. the cefradine injection of two-chamber bag packing as claimed in claim 1 is characterized in that the crude drug of this injection pharmaceutical composition consists of:
Powder chamber: cefradine 0.125 weight portion
Sap cavity: glucose injection: 100 parts by volume contain glucose 5 weight portions.
3. the cefradine injection of two-chamber bag packing as claimed in claim 1 is characterized in that the crude drug of this injection pharmaceutical composition consists of:
Powder chamber: cefradine 0.25 weight portion
Sap cavity: glucose injection: 250 parts by volume contain glucose 12.5 weight portions.
4. the cefradine injection of two-chamber bag packing as claimed in claim 1 is characterized in that the crude drug of this injection pharmaceutical composition consists of:
Powder chamber: cefradine 2 weight portions
Sap cavity: sodium chloride injection: 100 parts by volume sodium chloride-containing, 0.9 weight portion.
5. the cefradine injection of two-chamber bag packing as claimed in claim 1 is characterized in that the crude drug of this injection pharmaceutical composition consists of:
Powder chamber: cefradine 0.5 weight portion
Sap cavity: sodium chloride injection: 250 parts by volume sodium chloride-containing, 2.25 weight portions.
6. method for preparing like the cefradine injection of the arbitrary described two-chamber bag packing of claim 1-5 is characterized in that this method is:
Bag forming: use the film for transfusion of double-layer seal to process bag, the bag edge adopts real weldering sealing, and reserves the interface that is used for fill, is divided into two chambers of exerting pressure and can open with weak welding rod in the middle of the bag;
Medicinal liquid preparation: the preparation of glucose injection: take by weighing glucose by formula ratio and add an amount of water for injection to process concentration be 4%～11% solution;
The preparation of sodium chloride injection: take by weighing sodium chloride by formula ratio and add an amount of water for injection to process concentration be 0.8%～1% solution;
Liquid medicine filling, seal: the medicinal liquid for preparing is poured into the transfusion bag sap cavity through interface, and seal;
Sterilization: packaged sample is placed sterilizing installation, in 115 ℃～125 ℃ sterilizations 8～30 minutes.
Dry: the sample after will sterilizing descended dry 60-150 minute in 70-100 ℃.
The fill of aseptic powder: sample is fixed on the powder dispensing apparatus, under gnotobasis, cuts real welding rod on one side, the cefradine aseptic powder is quantitatively poured into the powder chamber after, firm slit edge edge is carried out real sealing mouth;
The welding of aluminium foil outside the powder chamber: with welding around aluminum film and the powder chamber.
7. the method for preparing of the cefradine injection of two-chamber bag packing as claimed in claim 6 is characterized in that this method is:
Use the film for transfusion of double-layer seal, process bag through the multicell bag making, filling and sealing machine, the bag edge adopts real weldering sealing, and reserves the interface that is used for fill, is divided into two chambers with weak welding rod in the middle of the bag; Taking by weighing glucose 5g adds the injection water and is settled to 100ml to process concentration be 5% solution; The medicinal liquid for preparing is poured into the transfusion bag sap cavity through interface, and the suitable accessory of welding composite cover or other seals; Packaged sample is placed steam autoclave, in 121 ℃ of sterilizations 12 minutes; Sample after the sterilization is following dry 100 minutes in 80 ℃; Sample is fixed on the full-automatic powder racking machine, under gnotobasis, cuts real welding rod on one side, the cefradine aseptic powder is poured into the powder chamber after, firm slit edge edge is carried out real sealing mouth; Adopt full-automatic laminating machine with welding around aluminum film and the powder chamber.
8. the method for preparing of the Azithromycin injection of two-chamber bag packing as claimed in claim 6 is characterized in that:
The concentration of said glucose injection is 5%;
In the said sealing process with composite cover or other and the corresponding accessory heat sealing of interface;
Sterilising temp in the said sterilization process is 121 ℃, and sterilization time is 12 minutes;
In the said drying process, baking temperature is 80 ℃, and be 100 minutes drying time;
The equipment that adopts in the welding sequence of aluminium foil outside the said powder chamber is full-automatic laminating machine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103864026A CN102429861A (en) | 2011-11-29 | 2011-11-29 | Double-cavity bag packaged cefradine injection and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103864026A CN102429861A (en) | 2011-11-29 | 2011-11-29 | Double-cavity bag packaged cefradine injection and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102429861A true CN102429861A (en) | 2012-05-02 |
Family
ID=45978451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103864026A Pending CN102429861A (en) | 2011-11-29 | 2011-11-29 | Double-cavity bag packaged cefradine injection and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102429861A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1408336A (en) * | 2001-10-03 | 2003-04-09 | 尼普洛株式会社 | Complex room container preparation |
| CN1751751A (en) * | 2005-09-07 | 2006-03-29 | 华北制药集团有限责任公司 | Immediate dispensing infusion |
| CN201784917U (en) * | 2010-09-17 | 2011-04-06 | 四川科伦药物研究有限公司 | Combined package for cefradine for injection |
-
2011
- 2011-11-29 CN CN2011103864026A patent/CN102429861A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1408336A (en) * | 2001-10-03 | 2003-04-09 | 尼普洛株式会社 | Complex room container preparation |
| CN1751751A (en) * | 2005-09-07 | 2006-03-29 | 华北制药集团有限责任公司 | Immediate dispensing infusion |
| CN201784917U (en) * | 2010-09-17 | 2011-04-06 | 四川科伦药物研究有限公司 | Combined package for cefradine for injection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018508575A (en) | Intravenous infusion dosage form | |
| CN106038538A (en) | Premixed preparation for dexmedetomidine | |
| WO2020109195A1 (en) | Manufacturing a flexible container | |
| CN102406543A (en) | Ceftazidime injection packaged by double-cavity bag and preparation method thereof | |
| CN102429860A (en) | Double-cavity bag packed cefpirome sulfate injection and preparation method thereof | |
| CN102429863A (en) | Azithromycin injection packed by double-cavity bag and preparation method thereof | |
| KR20040019299A (en) | Process for bulk autoclaving | |
| CN102429861A (en) | Double-cavity bag packaged cefradine injection and preparation method thereof | |
| CN102406544A (en) | Azithromycin lactobionateinjection solution packaged by double-cavity bag and preparation method | |
| KR20010080275A (en) | Bag for preserving and transporting sterile products in powder form and for forming solutions of said products in the bag | |
| US20190336443A1 (en) | Ready-To-Use Liquid Parenteral Formulations Of Ribavirin | |
| JP2001520183A (en) | Solution for peritoneal dialysis and method for producing the same | |
| KR0169505B1 (en) | Drug packing polyolefinic material, process for producing the same and container for drug packing | |
| CN101904822A (en) | Faropenem sodium freeze-drying powder and preparation method thereof | |
| CN1241532C (en) | Complex room container preparation | |
| CN208989864U (en) | Multi-cavity infusion bag | |
| CN106265491A (en) | A kind of clindamycin phosphate injection of Double-cavity bag packaging and preparation method thereof | |
| CN1274286A (en) | Parenteral formulations comprising carbamazepine or its derivatives | |
| CN208877298U (en) | A kind of powder liquid two-chamber transfusion bag for packing lactobionic acid azithromycin, sodium chloride injection | |
| Barnett et al. | Basics in clinical nutrition: parenteral nutrition admixtures, how to prepare parenteral nutrition (PN) admixtures | |
| CN104434517A (en) | Double-layer aseptic package, packaging method and sterility test method for large volume injections | |
| CN103263389A (en) | Cefoxitin sodium freeze-dried powder injection for injection and preparation method thereof | |
| CN104876949A (en) | Ceftazidime compound entity and preparation thereof for children | |
| CN104288099A (en) | Ibuprofen injection | |
| CN203123021U (en) | Large-volume powder liquid bag container |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120502 |